US FDA rejects Allergan inhaled migraine drug, again
This article was originally published in Scrip
Executive Summary
Allergan revealed on 16 April the US FDA rejected the company's experimental inhaled migraine drug Levadex (dihydroergotamine), citing concerns about the medicine's canister filling unit manufacturer Exemplar Pharma and the manufacturing process for the final filled canisters.